INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 13, Issue 3- 2026

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.03.002

Cloud-Based Genomic Platforms for Sickle Cell Disease Research: Opportunities, Challenges and Best Practices

***Emmanuel Ifeanyi Obeagu[1,2]**

[1]Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

[2]Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

*Corresponding Author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com,

ORCID: 0000-0002- 4538-0161

Abstract

Sickle cell disease (SCD) remains a major global health challenge, particularly in sub-Saharan Africa and among populations of African descent. Advances in genomic technologies have enhanced understanding of the genetic underpinnings of SCD, yet the effective storage, analysis, and sharing of vast genomic datasets demand robust computational infrastructure. Cloud-based genomic platforms offer scalable, cost-effective, and collaborative environments that can accelerate SCD research, enable precision medicine, and support large-scale genome-wide association studies (GWAS). This narrative review explores the opportunities these platforms present, including improved data accessibility, integration of multi-omics datasets, and global research collaboration. It also examines challenges such as data privacy, compliance with ethical guidelines, internet connectivity constraints in resource-limited settings, and the need for technical capacity building. Best practices for deploying and using cloud-based genomic systems in SCD research are proposed, with an emphasis on sustainable infrastructure, secure data governance, and equitable access. Leveraging cloud technologies can bridge the gap between genomic research advancements and clinical translation, ultimately improving outcomes for individuals living with SCD.

Keywords: *Sickle cell disease, Cloud computing, Genomic data, Bioinformatics, Data security*

Introduction

Sickle cell disease (SCD) is one of the most common inherited hemoglobinopathies worldwide, affecting millions of individuals and contributing to significant morbidity and mortality. It results from a single nucleotide substitution in the β-globin gene (HBB), leading to the production of abnormal hemoglobin S (HbS) [1-2]. Under deoxygenated conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle-like shape. This morphological alteration underlies the chronic hemolysis, vaso-occlusion, and multi-organ complications characteristic of the disease. While SCD has a global presence, the highest burden lies in sub-Saharan Africa, where limited healthcare resources exacerbate disease outcomes. Migration patterns have also increased its prevalence in Europe, the Middle East, and the Americas, making SCD a worldwide public health concern [3-4].Over the past two decades, genomic research has revolutionized the understanding of SCD pathophysiology. Genome-wide association studies (GWAS), whole-genome sequencing (WGS), and transcriptomic analyses have identified genetic modifiers that influence disease severity, such as variants in BCL11A, HBS1L-MYB, and KLF1. These discoveries have informed precision medicine approaches aimed at stratifying patients by risk, predicting treatment responses, and identifying novel therapeutic targets. Moreover, the increasing use of multi-omics approaches—including proteomics, metabolomics, and epigenomics—has created unprecedented opportunities for a more comprehensive understanding of disease mechanisms [5-6].

Despite these advancements, the generation of genomic data for SCD presents substantial computational challenges. Large-scale sequencing projects produce terabytes to petabytes of data that require secure, scalable storage and high-performance analytical capabilities. Traditional on-premises computational systems in many research institutions, particularly in low- and middle-income countries, are inadequate to handle such volumes of data. The lack of robust computational infrastructure not only limits data analysis but also hinders collaboration between research groups, slowing the pace of discovery [7].Cloud-based genomic platforms have emerged as a viable and transformative solution to these challenges. By providing on-demand computational power, virtually unlimited storage, and integrated bioinformatics pipelines, cloud services such as Amazon Web Services (AWS), Google Cloud Platform (GCP), and Microsoft Azure are enabling researchers to process, analyze, and share large genomic datasets efficiently. Specialized platforms like DNAnexus, Seven Bridges, and Terra have tailored their services to meet the needs of genomic scientists, offering user-friendly interfaces, workflow automation, and compliance with key data security regulations [8-9].

For SCD research, cloud platforms hold particular promise. They allow for the integration of genomic data with clinical, epidemiological, and environmental datasets, which is critical for understanding the heterogeneity of disease phenotypes across populations. These platforms also enable global collaborations, bridging the gap between high-resource and low-resource settings by providing equitable access to advanced computational tools. Additionally, cloud solutions reduce the need for costly on-site infrastructure and maintenance, making them more accessible for institutions in resource-limited environments [10].However, the adoption of cloud-based genomic platforms in SCD research is not without obstacles. Data security, privacy, and regulatory compliance remain significant concerns, especially given the sensitivity of genomic information. The digital divide—manifested as disparities in internet bandwidth, computing literacy, and technical expertise—limits the ability of many research institutions in high-burden countries to fully leverage cloud solutions. Furthermore, cost models for cloud services can be prohibitive for long-term projects without sustained funding support, underscoring the need for financial sustainability strategies [11].

Given the transformative potential of cloud-based genomic platforms and the critical role of genomics in advancing SCD research, this

narrative review aims to explore the opportunities, challenges, and best practices for their effective implementation. We highlight how cloud solutions can enhance data analysis, foster collaborative research networks, and accelerate translation from genomic discovery to clinical application. We also address technical, ethical, and infrastructural considerations, offering recommendations to guide researchers, policymakers, and funding agencies in harnessing cloud technologies for the benefit of individuals living with SCD worldwide.

Aim

The aim of this narrative review is to examine the role of cloud-based genomic platforms in advancing sickle cell disease (SCD) research, with a focus on their potential to enhance data storage, analysis, and collaborative efforts

Methods

This review was conducted using a narrative approach to synthesize existing literature on cloud-based genomic platforms and their application in sickle cell disease (SCD) research. A comprehensive search of peer-reviewed articles, conference proceedings, and relevant reports was performed across major scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar, up to July 2025. Search terms combined keywords and Boolean operators, including: *"sickle cell disease"*, *"cloud computing"*, *"genomic platforms"*, *"bioinformatics"*, *"data security"*, and *"multi-omics"*. Sources were selected based on their relevance to at least one of the review objectives: (1) describing the functionalities and capabilities of cloud-based genomic platforms, (2) evaluating their current or potential role in SCD research, or (3) discussing challenges and best practices in their deployment. Priority was given to studies presenting empirical findings, case studies, or well-substantiated expert opinions. Grey literature, such as policy documents, technology white papers, and guidelines from cloud service providers, was included where it provided technical or ethical insights not available in peer-reviewed publications.

The gathered literature was critically appraised for credibility, scope, and contextual relevance, particularly with respect to application in both high-resource and resource-limited settings. Findings were organized thematically into opportunities, challenges, and best practices, ensuring a balanced representation of technical, ethical, and infrastructural perspectives. No formal meta-analysis was performed due to the heterogeneity of study designs and outcome measures; instead, the narrative synthesis emphasizes trends, recurring themes, and actionable recommendations for stakeholders in SCD genomic research.

Opportunities in Cloud-Based Genomic Research for SCD

Cloud-based genomic platforms present transformative opportunities for advancing sickle cell disease (SCD) research by addressing long-standing limitations in data storage, computational capacity, and global collaboration. One of the most significant advantages is the ability to manage and analyze massive genomic datasets without the need for costly on-premises infrastructure. Large-scale initiatives such as whole-genome sequencing (WGS) projects and genome-wide association studies (GWAS) generate terabytes of data that can be stored, processed, and accessed in secure, scalable cloud environments. This flexibility allows researchers in both high-resource and low-resource settings to participate in large genomic studies without being constrained by local hardware limitations [12-13].Another major opportunity lies in the integration of diverse data types. SCD is a complex disorder influenced not only by genetic mutations in the β-globin gene but also by genetic modifiers, environmental factors, and epigenetic changes. Cloud platforms enable the integration of genomic data with transcriptomic, proteomic, metabolomic, and clinical datasets, facilitating

multi-omics research that can reveal novel biomarkers, therapeutic targets, and genotype–phenotype correlations. This capacity for integrated analysis supports precision medicine approaches, where patient-specific data can inform tailored treatment strategies such as gene editing or targeted drug therapies [14-15].

Cloud platforms also enhance collaborative research across geographical boundaries. By providing centralized access to datasets and computational tools, these platforms eliminate the need for physical data transfer, which can be time-consuming and prone to security risks. Researchers from different institutions and countries can work on shared projects in real time, applying standardized analytical workflows and ensuring reproducibility. This is particularly important for SCD research, which requires large, diverse datasets to capture population-specific genetic variation and understand regional differences in disease expression [16].Furthermore, cloud-based systems can democratize access to advanced bioinformatics tools. Many commercial and open-source genomic analysis pipelines—ranging from sequence alignment to variant calling and functional annotation—are pre-configured within cloud environments, reducing the technical barrier for researchers with limited computational training. This accessibility supports capacity building, enabling more scientists in resource-limited regions to conduct high-quality genomic analyses and contribute to global knowledge generation [17].

From a cost perspective, cloud platforms offer a pay-as-you-go model, allowing research groups to scale computational resources up or down based on project needs. This model reduces the financial burden of purchasing and maintaining high-performance computing clusters, making genomic research more feasible for smaller institutions and projects with limited budgets. Additionally, many cloud service providers offer grants, credits, or discounted services for academic and non-profit research, further expanding accessibility [17]. Cloud platforms can play a pivotal role in accelerating translational research for SCD. By linking genomic data with longitudinal clinical records in secure environments, these systems support predictive modeling of disease progression, drug response, and complications such as stroke or organ failure. This capability has the potential to inform clinical decision-making, guide public health strategies, and ultimately improve patient outcomes. When coupled with machine learning and artificial intelligence tools, cloud environments can uncover complex patterns and predictive markers that may be overlooked by conventional analysis methods(Table 1) [18].

Table 1: Opportunities in Cloud-Based Genomic Research for SCD

Opportunity	Description	Potential Impact on SCD Research
Scalable Storage & Computing	Cloud platforms provide virtually unlimited storage and high-performance computing for large genomic datasets.	Enables analysis of whole-genome, transcriptomic, and multi-omic data at scale, accelerating discovery of SCD modifiers.
Multi-Institutional Collaboration	Shared workspaces and harmonized pipelines facilitate global collaboration.	Enhances inclusion of diverse populations, standardizes data, and promotes cross-institutional research in SCD-endemic regions.
Access to Advanced Analytical Tools	Integrated bioinformatics tools, machine learning frameworks, and visualization platforms are available on cloud environments.	Supports variant annotation, polygenic risk modeling, and precision medicine applications for SCD.
Enhanced Data Security &	Cloud providers offer HIPAA, GDPR, and regional compliance frameworks.	Protects sensitive patient genomic data, fostering trust and ethical research

Compliance		practices.
Facilitating Precision Medicine	Cloud analytics enable genotype–phenotype modeling, pharmacogenomics, and population-specific allele mapping.	Supports tailored interventions, risk prediction, and therapeutic optimization for individuals with SCD.
Remote Accessibility	Researchers can securely access data and tools from any location with internet connectivity.	Promotes participation of LMIC researchers and reduces geographic barriers to high-quality genomic research.

Challenges and Barriers

While cloud-based genomic platforms hold immense promise for advancing sickle cell disease (SCD) research, their adoption and effective utilization face several technical, ethical, and infrastructural obstacles. A primary concern is the issue of data security and patient privacy. Genomic information is inherently sensitive, carrying implications not only for the individual but also for family members and communities. Unauthorized access, data breaches, or misuse of genetic information could result in discrimination, stigmatization, or violation of patient rights. Consequently, ensuring compliance with stringent regulations such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States is critical but often complex, particularly in multi-country research collaborations [19-21].Regulatory variability further complicates the landscape. Different countries have varying rules regarding the storage, transfer, and sharing of genomic data, and some impose restrictions on hosting data outside national borders. This regulatory fragmentation can slow down cross-border collaborations, which are essential for assembling large, diverse datasets needed for robust SCD research. Establishing standardized data governance frameworks that satisfy multiple jurisdictions remains a significant challenge [22].
Infrastructure limitations present another major barrier, especially in regions with the highest SCD burden. Reliable high-speed internet connectivity is a prerequisite for efficiently using cloud-based platforms, yet many research institutions in sub-Saharan Africa and other low-resource settings struggle with inconsistent bandwidth and frequent network disruptions. These limitations hinder the ability to upload, download, and process large genomic datasets in real time, ultimately slowing research progress [23-24].Financial sustainability also poses a challenge. Although cloud computing can be cost-effective compared to maintaining high-performance local servers, the cumulative costs of long-term data storage, analysis, and subscription services can become prohibitive for projects without stable funding. Budgetary constraints may lead to reliance on intermittent grants or donated cloud credits, which, while valuable, do not provide a sustainable foundation for continuous genomic research [25].

A further barrier is the shortage of skilled personnel trained in computational genomics, bioinformatics, and cloud infrastructure management. Even when cloud resources are available, a lack of expertise in workflow design, data interpretation, and security configuration can limit their effective use. Without targeted training and capacity-building initiatives, the potential of cloud platforms may remain underutilized in high-burden regions [26].Trust and ethical considerations also play a critical role. Communities affected by SCD, particularly in historically underserved regions, may be hesitant to participate in genomic research due to concerns about exploitation, misuse of data, or lack of direct benefit sharing. Building trust requires transparent communication, culturally sensitive consent processes, and mechanisms to ensure that local populations benefit from research outcomes [27-29].

In addition, the digital divide between high-resource and low-resource settings risks perpetuating inequities in genomic medicine. Institutions in well-funded regions may rapidly advance in cloud-based genomic research, while

those in resource-limited areas struggle to keep pace, widening global disparities in both research output and access to emerging precision medicine interventions. Bridging this gap will require coordinated efforts from governments, funding agencies, technology providers, and the global scientific community [30-31].

Best Practices for Implementation

Maximizing the potential of cloud-based genomic platforms for sickle cell disease (SCD) research requires a strategic approach that balances technical efficiency with ethical responsibility and sustainability. The first cornerstone is robust data governance. Institutions should adopt clear policies that define how genomic data is collected, stored, accessed, and shared. Encryption, role-based access controls, and regular security audits are essential to prevent unauthorized access and ensure compliance with international regulations such as GDPR and HIPAA. Where cross-border collaborations are involved, data-sharing agreements should align with all relevant national laws while maintaining the highest standards of privacy protection [32].Equally important is capacity building in computational genomics and cloud infrastructure management. Researchers, bioinformaticians, and data managers in SCD-endemic regions should have access to targeted training programs covering cloud-based workflows, security protocols, and multi-omics integration. Partnerships between high-resource and low-resource institutions can facilitate skill transfer, while cloud service providers can support capacity building through sponsored training and technical support programs. Such efforts ensure that cloud adoption is accompanied by local expertise capable of sustaining its use [33].

Collaborative frameworks form another best practice, as cloud-based platforms inherently lend themselves to multi-institutional projects. Standardized protocols for data formatting, annotation, and workflow automation can enhance reproducibility and interoperability between research teams. Platforms like Terra, DNAnexus, and Seven Bridges allow for version-controlled analysis pipelines, ensuring that results are consistent across sites. Establishing international SCD research consortia with shared cloud resources can accelerate discoveries while reducing duplication of effort [34-35].To address financial sustainability, research programs should adopt a mixed funding approach that combines grants, institutional investment, and industry partnerships. Many cloud providers offer academic credits, non-profit discounts, and storage optimization tools—such as automated archiving of infrequently accessed data—to reduce costs. Careful monitoring of cloud usage and cost forecasting can prevent budget overruns, ensuring that resources remain available throughout the project lifecycle [36].

Infrastructure readiness is another critical factor. Research institutions should assess and, where possible, improve internet bandwidth, stability, and redundancy before migrating to cloud-based workflows. In areas with limited connectivity, hybrid solutions that combine local processing with periodic cloud synchronization can bridge the gap until full infrastructure upgrades are feasible. Additionally, establishing regional cloud access points in high-prevalence areas could reduce latency and improve data transfer efficiency [35].Integrating ethical and equity principles into best practices is essential to ensure fair participation and benefit sharing. Community engagement should begin early in the research process, with transparent communication about how genomic data will be used and what potential benefits can be expected. Researchers should prioritize returning relevant results to participating communities, either through clinical translation or capacity-strengthening initiatives. Equitable access to cloud resources must be a central policy goal to prevent widening disparities in genomic research and healthcare outcomes [34].

Continuous evaluation and adaptation should be embedded into the implementation process. Cloud technologies evolve rapidly, and best practices must be regularly updated to reflect emerging security threats, new analytical tools, and

improved cost-efficiency strategies. Regular feedback from end-users—both researchers and community stakeholders—can guide platform optimization, ensuring that cloud solutions remain relevant, secure, and impactful in advancing SCD research [36].

Ethical and Equity Considerations

The integration of cloud-based genomic platforms into sickle cell disease (SCD) research introduces important ethical responsibilities that extend beyond technical implementation. Central to these responsibilities is the protection of participant autonomy and the safeguarding of sensitive genetic information. Informed consent processes must clearly explain the scope of data collection, how genomic information will be stored and shared, and the potential risks and benefits of participation. Because genomic data has implications not only for individuals but also for their families and communities, consent frameworks should also address long-term storage and possible secondary uses of data, ensuring that participants understand and agree to these terms [37].Equity considerations are equally critical. SCD disproportionately affects populations in sub-Saharan Africa, India, the Middle East, and other historically underserved regions, yet these same regions often have limited capacity to participate fully in genomic research. Without deliberate strategies to ensure equitable access, cloud-based platforms risk reinforcing existing disparities, enabling well-resourced institutions to advance rapidly while low-resource settings lag behind. Funding bodies, governments, and technology providers must therefore prioritize infrastructure development, capacity building, and subsidized access to cloud resources in high-burden regions to prevent the widening of the global genomic divide [38].

Community trust forms the foundation of ethical genomic research. Historical instances of exploitation, lack of benefit sharing, and limited return of results have created skepticism toward research initiatives in many affected communities. To address this, researchers must actively engage communities from the earliest stages of project planning. Engagement should involve not only disseminating information but also seeking input on study design, data usage, and benefit-sharing mechanisms. Benefits may include direct clinical applications, public health interventions, or investment in local scientific infrastructure. Transparent reporting of findings and culturally sensitive communication of results can further strengthen trust and encourage sustained community participation [39].The principle of reciprocity should guide international collaborations in SCD genomics. Research conducted in high-prevalence but low-resource regions should generate tangible benefits for those communities, such as improved diagnostic capabilities, access to new therapies, or training opportunities for local scientists. Additionally, data-sharing agreements must ensure that contributing researchers from these regions receive proper recognition and authorship in scientific publications, avoiding the “parachute research” model where data is extracted without equitable intellectual contribution [40-41].

Ethical stewardship in cloud-based genomic research requires ongoing oversight. Ethics review committees and institutional review boards should be trained to evaluate the unique considerations of cloud storage, cross-border data transfer, and large-scale data analytics. As technology evolves, ethical frameworks must be revisited to incorporate emerging risks, such as the re-identification of anonymized data or biases in artificial intelligence algorithms applied to genomic datasets. By embedding equity and ethics into every stage of cloud-based SCD research, the global scientific community can ensure that technological advancements translate into fair, inclusive, and lasting health benefits [42].

Future Directions

The future of cloud-based genomic platforms in sickle cell disease (SCD) research is poised to be shaped by emerging technologies, evolving data

governance frameworks, and growing international collaboration. One of the most promising developments is the integration of artificial intelligence (AI) and machine learning (ML) into cloud-based workflows. These tools can rapidly analyze complex, multi-dimensional datasets to uncover novel genetic modifiers, predict disease progression, and identify patient subgroups that may benefit from targeted therapies. AI-driven approaches also have the potential to accelerate drug discovery pipelines by modeling therapeutic responses in silico before clinical trials, reducing both cost and time to treatment availability [43].Another key advancement lies in federated learning models, which allow for collaborative data analysis without transferring raw data across borders. In this approach, algorithms are sent to local datasets stored in secure environments, and only model parameters—not sensitive data—are shared back to a central system. This method could address both privacy concerns and regulatory barriers, enabling large-scale global studies while maintaining compliance with local data protection laws. For SCD research, such models could facilitate meta-analyses of genetic variation and treatment outcomes across diverse populations without compromising individual privacy [44].

Blockchain technology is also likely to play a role in future genomic data management. By providing transparent, immutable records of data access and transactions, blockchain could enhance trust in how sensitive SCD genomic data is handled. This could be especially valuable in multi-institutional projects where ensuring accountability and traceability is critical [45].In terms of infrastructure, regional genomic data hubs connected via secure cloud networks could help bridge connectivity gaps in low-resource settings. These hubs would allow local researchers to upload and process data without relying on high-latency international networks, while still enabling global collaborations through synchronized cloud repositories. Coupled with continued investment in internet infrastructure, such hubs could significantly reduce the digital divide in SCD genomic research [46].On the policy front, global standards for genomic data sharing—developed collaboratively by governments, research institutions, and technology providers—will be essential. These standards should harmonize ethical, legal, and technical requirements to facilitate international research while ensuring participant protection. Future frameworks may also include built-in benefit-sharing mechanisms that guarantee that high-burden communities directly benefit from research conducted on their genomic data [47].
Expanding capacity-building initiatives will be critical to ensure sustainable use of cloud platforms. This includes developing advanced training programs in bioinformatics, AI, and data governance, as well as creating mentorship networks that connect researchers in low-resource regions with global experts. By combining cutting-edge technology with equitable access and strong ethical safeguards, the next phase of cloud-based SCD genomic research can be both scientifically transformative and socially responsible [48].

Conclusion

Cloud-based genomic platforms represent a pivotal advancement in sickle cell disease (SCD) research, offering scalable, cost-effective, and collaborative solutions to the challenges posed by large and complex genomic datasets. These platforms enable the integration of multi-omics data, foster global research partnerships, and democratize access to advanced bioinformatics tools, thereby accelerating discovery and precision medicine efforts. However, significant challenges remain, including data security, regulatory compliance, infrastructure limitations, and capacity gaps, particularly in regions most affected by SCD. By adopting best practices that emphasize robust data governance, capacity building, equitable access, and ethical engagement, the global research community can harness cloud technologies to bridge existing disparities and improve clinical outcomes. Looking forward, emerging innovations such as artificial intelligence, federated learning, and blockchain, alongside supportive policy frameworks, promise to enhance the security, efficiency, and inclusivity of cloud-based SCD genomics.

References

1. Inusa BPD, Hsu LL, Kohli N, Patel A, Ominu-Evbota K, Anie KA, Atoyebi W. Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment. Int J Neonatal Screen. 2019;5(2):20. doi: 10.3390/ijns5020020.
2. Ansari J, Moufarrej YE, Pawlinski R, Gavins FNE. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. Expert Rev Hematol. 2018;11(1):45-55. doi: 10.1080/17474086.2018.1407240.
3. Obeagu EI, Olateju OR. Integrating sickle cell disease care into primary healthcare in Uganda: a narrative review. Ann Med Surg (Lond). 2025;87(9):5918-5924. doi: 10.1097/MS9.0000000000003713.
4. Obeagu EI. Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. Ann Med Surg (Lond). 2025;87(6):3279-3288. doi: 10.1097/MS9.0000000000002981.
5. Tsukahara K, Chang X, Mentch F, Smith-Whitley K, Bhandari A, Norris C, Glessner JT, Hakonarson H. Identification of genetic variants associated with clinical features of sickle cell disease. Sci Rep. 2024;14(1):20070. doi: 10.1038/s41598-024-70922-5.
6. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012;87(8):795-803. doi: 10.1002/ajh.23232.
7. Schadt EE, Linderman MD, Sorenson J, Lee L, Nolan GP. Computational solutions to large-scale data management and analysis. Nat Rev Genet. 2010;11(9):647-57. doi: 10.1038/nrg2857.
8. Liu B, Madduri RK, Sotomayor B, Chard K, Lacinski L, Dave UJ, Li J, Liu C, Foster IT. Cloud-based bioinformatics workflow platform for large-scale next-generation sequencing analyses. J Biomed Inform. 2014; 49:119-33. doi: 10.1016/j.jbi.2014.01.005.
9. Langmead B, Nellore A. Cloud computing for genomic data analysis and collaboration. Nat Rev Genet. 2018;19(4):208-219. doi: 10.1038/nrg.2017.113.
10. Isokpehi RD, Johnson CP, Tucker AN, Guatam A, Brooks TJ, Johnson MO, Cozart T, Wathington DJ. Integrating Datasets on Public Health and Clinical Aspects of Sickle Cell Disease for Effective Community-Based Research and Practice. Diseases. 2020;8(4):39. doi: 10.3390/diseases8040039.
11. Charlebois K, Palmour N, Knoppers BM. The Adoption of Cloud Computing in the Field of Genomics Research: The Influence of Ethical and Legal Issues. PLoS One. 2016;11(10): e0164347. doi: 10.1371/journal.pone.0164347.
12. Dahlquist JM, Nelson SC, Fullerton SM. Cloud-based biomedical data storage and analysis for genomic research: Landscape analysis of data governance in emerging NIH-supported platforms. HGG Adv. 2023;4(3):100196. doi: 10.1016/j.xhgg.2023.100196.
13. Obeagu EI. Thrombosis risk in sickle cell disease with HIV co-infection: unraveling the complex interactions and clinical implications - a narrative review. Ann Med Surg (Lond). 2025;87(8):5070-5076. doi: 10.1097/MS9.0000000000003533.
14. Brazel AJ, Vernimmen D. The complexity of epigenetic diseases. J Pathol. 2016;238(2):333-344. doi: 10.1002/path.4647.
15. Zoghbi HY, Beaudet AL. Epigenetics and Human Disease. Cold Spring HarbPerspect Biol. 2016;8(2): a019497. doi: 10.1101/cshperspect. a019497.
16. Grossman RL, Boyles RR, Davis-Dusenbery BN, Haddock A, Heath AP, O'Connor BD, Resnick AC, Taylor DM, Ahalt S. A Framework for the Interoperability of Cloud Platforms: Towards FAIR Data in SAFE Environments. Sci Data. 2024;11(1):241. doi: 10.1038/s41597-024-03041-5.
17. Krampis K. Democratizing bioinformatics through easily accessible software platforms for non-experts in the field. Biotechniques. 2022;72(2):36-38. doi: 10.2144/btn-2021-0060.
18. Li H, Wang J, Liu H. Empowering Precision Medicine for Rare Diseases through Cloud Infrastructure Refactoring. AMIA Jt Summits Transl Sci Proc. 2025; 2025:300-311.

19. Wonkam A. The future of sickle cell disease therapeutics rests in genomics. Dis Model Mech. 2023;16(2): dmm049765. doi: 10.1242/dmm.049765.
20. Obeagu EI. Clotting, inflammation, and immunity: the multifaceted role of platelets in HIV and sickle cell disease - a narrative review. Ann Med Surg (Lond). 2025;87(9):5878-5886. doi: 10.1097/MS9.0000000000003677.
21. Obeagu EI. Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review. Ann Med Surg (Lond). 2025;87(9):5775-5783. doi: 10.1097/MS9.0000000000003619.
22. Wang Z, Gregg B, Du L. Regulatory barriers to US-China collaboration for generative AI development in genomic research. Cell Genom. 2024;4(6):100564. doi: 10.1016/j.xgen.2024.100564.
23. Awosiku OV, Gbemisola IN, Oyediran OT, Egbewande OM, Lami JH, Afolabi D, Okereke M, Effiong F. Role of digital health technologies in improving health financing and universal health coverage in Sub-Saharan Africa: a comprehensive narrative review. Front Digit Health. 2025; 7:1391500. doi: 10.3389/fdgth.2025.1391500.
24. Sachdeva S, Bhatia S, Al Harrasi A, Shah YA, Anwer K, Philip AK, Shah SFA, Khan A, Ahsan Halim S. Unraveling the role of cloud computing in health care system and biomedical sciences. Heliyon. 2024;10(7): e29044. doi: 10.1016/j.heliyon. 2024.e29044.
25. Huang YN, Munteanu V, Love MI, Ronkowski CF, Deshpande D, Wong-Beringer A, Corbett-Detig R, Dimian M, Moore JH, Garmire LX, Reddy TBK, Butte AJ, Robinson MD, Eskin E, Abedalthagafi MS, Mangul S. Perceptual and technical barriers in sharing and formatting metadata accompanying omics studies. Cell Genom. 2025;5(5):100845. doi: 10.1016/j.xgen.2025.100845.
26. Munung NS, Nnodu OE, Moru PO, Kalu AA, Impouma B, Treadwell MJ, Wonkam A. Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa. Gene Ther. 2024;31(5-6):202-208. doi: 10.1038/s41434-023-00429-7.
27. Anie KA, Olayemi E, Paintsil V, Owusu-Dabo E, Adeyemo TA, Sani MU, Galadanci NA, Nnodu O, Tluway F, Adjei DN, Mensah P, Sarfo-Antwi J, Nwokobia H, Gambo A, Benjamin A, Salim A, Osae-Larbi JA, Ofori-Acquah SF; SickleGenAfrica Network. Sickle Cell Disease Genomics of Africa (SickleGenAfrica) Network: ethical framework and initial qualitative findings from community engagement in Ghana, Nigeria and Tanzania. BMJ Open. 2021;11(7): e048208. doi: 10.1136/bmjopen-2020-048208.
28. Obeagu EI. Public-private partnerships in tackling sickle cell disease in Uganda: a narrative review. Ann Med Surg (Lond). 2025;87(6):3339-3355. doi: 10.1097/MS9.0000000000003082.
29. Bombard Y, Hayeems RZ. How digital tools can advance quality and equity in genomic medicine. Nat Rev Genet. 2020;21(9):505-506. doi: 10.1038/s41576-020-0260-x.
30. Adebamowo SN, Francis V, Tambo E, Diallo SH, Landouré G, Nembaware V, Dareng E, Muhamed B, Odutola M, Akeredolu T, Nerima B, Ozumba PJ, Mbhele S, Ghanash A, Wachinou AP, Ngomi N. Implementation of genomics research in Africa: challenges and recommendations. Glob Health Action. 2018;11(1):1419033. doi: 10.1080/16549716.2017.1419033.
31. Rahimzadeh V, Nelson SC, Thorogood A, Lawson J, Fullerton SM. Ethical governance for genomic data science in the cloud. Nat Rev Genet. 2025;26(2):75-77. doi: 10.1038/s41576-024-00789-9.
32. Nnodu OE, Osei-Akoto A, Nembaware V, Kent J, Nwegbu M, Minja I, Mazandu GK, Makani J, Wonkam A. Skills Capacity Building for Health Care Services and Research Through the Sickle Pan African Research Consortium. Front Genet. 2022; 13:805806. doi: 10.3389/fgene.2022.805806.
33. Grossman RL, Boyles RR, Davis-Dusenbery BN, Haddock A, Heath AP, O'Connor BD, Resnick AC, Taylor DM, Ahalt S. A Framework for the Interoperability of Cloud Platforms: Towards FAIR Data in SAFE

Environments. Sci Data. 2024;11(1):241. doi: 10.1038/s41597-024-03041-5.
34. Jentsch M, Schneider-Lunitz V, Taron U, Braun M, Ishaque N, Wagener H, Conrad C, Twardziok S. Creating cloud platforms for supporting FAIR data management in biomedical research projects. F1000Res. 2024; 13:8. doi: 10.12688/f1000research.140624.3.
35. Xia Y, Yin Y. Research on the Impact of the Synergy Between Financial Technology and Green Finance on Environmental Efficiency. Sustainability. 2025; 17(9):4109. https://doi.org/10.3390/su17094109
36. Lee SS. The Ethics of Consent in a Shifting Genomic Ecosystem. Annu Rev Biomed Data Sci. 2021; 4:145-164. doi: 10.1146/annurev-biodatasci-030221-125715.
37. Raman V, Seshadri T, Joice SV, N Srinivas P. Sickle cell disease in India: a scoping review from a health systems perspective to identify an agenda for research and action. BMJ Glob Health. 2021;6(2): e004322. doi: 10.1136/bmjgh-2020-004322.
38. Atutornu J, Milne R, Costa A, Patch C, Middleton A. Towards equitable and trustworthy genomics research. EBioMedicine. 2022; 76:103879. doi: 10.1016/j.ebiom.2022.103879.
39. Kuona P, Kandawasvika GQ, Chunda-Liyoka C, Ruredzo IM, Sambo PM, Gorejena-Chidawanyika P, Mantina HM, Mtisi TJ, Phiri C, Chikara L, Kaweme NM, Chivige E, Namushi J, Maboreke TC, Athale U, Masimirembwa C. Sickle hemoglobinopathy research in Zimbabwe and Zambia: setting up an international sickle cell disease registry. Front Med (Lausanne). 2025; 12:1484763. doi: 10.3389/fmed.2025.1484763.
40. Minja IK, Nkya S, Bukini D, Mahenge N, Masamu U, Manongi J, Mgaya J, Mtiiye F, Nkanyemka M, Kisali EP, Mwinchande Mahawi I, Rifai A, Jonathan A, Nembaware V, Jonas M, Mulder N, Namazi R, Munube D, Paintsil V, Sangeda RZ, Ackerman H, Parker R, Sarfo FS, Guindo A, Nnodu OE, Balandya E, Kiguli S, Chunda-Liyoka C, Kuona P, Peprah E, Kamuhabwa A, Makani J. Strengthening global partnerships for sustainable sickle cell disease care: insights from SickleInAfrica at the 77th United Nations General Assembly and the US-Africa Leaders' Summit. BMJ Glob Health. 2025;10(3): e017154. doi: 10.1136/bmjgh-2024-017154.
41. Rahimzadeh V, Nelson SC, Thorogood A, Lawson J, Fullerton SM. Ethical governance for genomic data science in the cloud. Nat Rev Genet. 2025;26(2):75-77. doi: 10.1038/s41576-024-00789-9.
Collado A, Boaro MP, van der Veen S, Idrizovic A, Biemond BJ, Beneitez Pastor D, Ortuño A, Cela E, Ruiz-Llobet A, Bartolucci P, de Montalembert M, Castellani G, Biondi R, Manara R, Sanavia T, Fariselli P, Kountouris P, Kleanthous M, Alvarez F, Zazo S, Colombatti R, van Beers EJ, Mañú-Pereira MDM. Challenges and Opportunities of Precision Medicine in Sickle Cell Disease: Novel European Approach by GenoMed4All Consortium and ERN-EuroBloodNet. Hemasphere. 2023;7(3): e844. doi: 10.1097/HS9.0000000000000844.
42. Li N, Lewin A, Ning S, Waito M, Zeller MP, Tinmouth A, Shih AW; Canadian Transfusion Trials Group. Privacy-preserving federated data access and federated learning: Improved data sharing and AI model development in transfusion medicine. Transfusion. 2025;65(1):22-28. doi: 10.1111/trf.18077.
43. Al-Khasawneh MA, Faheem M, Alarood AA, Habibullah S, Alzahrani A. A secure blockchain framework for healthcare records management systems. Healthc Technol Lett. 2024;11(6):461-470. doi: 10.1049/htl2.12092.
44. Dahlquist JM, Nelson SC, Fullerton SM. Cloud-based biomedical data storage and analysis for genomic research: Landscape analysis of data governance in emerging NIH-supported platforms. HGG Adv. 2023;4(3):100196. doi: 10.1016/j.xhgg.2023.100196.
45. Knoppers BM. Framework for responsible sharing of genomic and health-related data. Hugo J. 2014;8(1):3. doi: 10.1186/s11568-014-0003-1.

46. Galiwango R, Whalen CJ, Kebirungi G, Atwine MT, Kimera R, Ssekagiri A, Kimbowa TW, Lukyamuzi E, Nsubuga M; eLwazi ODSP; Ssentongo L, Mutegeki H, Fonner JM, Wuerthwein F, Berman A, Okalebo LB, McCarthy M, Kramer VS, Quinones M, Cruz P, Hurt D, Giovanni MY, Mulder N, Tartakovsky M, Kayondo J, Jjingo D. Ten simple rules for building and maintaining sustainable high-performance computing infrastructure for research in resource-limited settings. PLoSComput Biol. 2025;21(9): e1013481. doi: 10.1371/journal.pcbi.1013481.
47. Jjingo D, Mboowa G, Sserwadda I, Kakaire R, Kiberu D, Amujal M, Galiwango R, Kateete D, Joloba M, Whalen CC. Bioinformatics mentorship in a resource limited setting. Brief Bioinform. 2022;23(1): bbab399. doi: 10.1093/bib/bbab399.

Abbreviations

AWS – Amazon Web Services
DNA – Deoxyribonucleic Acid
DNAnexus – A cloud-based genomic data analysis and management platform
FAIR – Findable, Accessible, Interoperable, Reusable
GATK – Genome Analysis Toolkit
GDP – Gross Domestic Product
GDPR – General Data Protection Regulation
HBB – Hemoglobin Subunit Beta Gene
HPC – High-Performance Computing
HIPAA – Health Insurance Portability and Accountability Act
LMICs – Low- and Middle-Income Countries
NIH – National Institutes of Health
SCD – Sickle Cell Disease
WDL – Workflow Description Language
WGS – Whole-Genome Sequencing

Access this Article in Online	
	Website: www.ijcrcps.com
Quick Response Code	Subject: Bioinformatics
DOI: 10.22192/ijcrcps.2026.13.03.002	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2026). Cloud-Based Genomic Platforms for Sickle Cell Disease Research: Opportunities, Challenges and Best Practices. Int. J. Curr. Res. Chem. Pharm. Sci. 13(3): 8-19.
DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.03.002

